Pulmonary Mycobacterium abscessus and response to treatment in an outpatient setting: Case series

被引:3
作者
Gopalaswamy, Radha [1 ]
Padmapriyadarsini, Chandrasekaran [2 ]
Sekar, Krithikaa [2 ]
Vijayaragavan, Vaishnavee [1 ]
Bhavani, Perumal Kannabiran [2 ]
Lokanathan, Lakshana Malla [2 ]
Anandakrishnan, Sundararajaperumal [3 ]
Sivaramakrishnan, Gomathi [1 ]
机构
[1] ICMR Natl Inst Res TB, Dept Bacteriol, Chennai, Tamil Nadu, India
[2] ICMR Natl Inst Res TB, Dept Clin Res, 1 Mayor Sathyamoorthy Rd, Chennai 600031, Tamil Nadu, India
[3] Rajiv Gandhi Govt Gen Hosp, Dept Thorac Med, Chennai, Tamil Nadu, India
关键词
Antibiotics; line probe assay; Mycobacterium abscessus; oral macrolide; pulmonary disease; INFECTION; DISEASE;
D O I
10.4103/ijmy.ijmy_22_21
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Pulmonary disease due to Mycobacterium abscessus (Mab) has become an increasing cause of health concern, particularly among individuals infected with nontuberculous mycobacteria. Since Mab is intrinsically resistant to many antibiotics, it is very challenging to treat patients with symptomatic disease. In this case series, we report four patients with symptomatic pulmonary Mab who had prior history of antituberculosis treatment intake and declared cured at the end of treatment. The current episode was confirmed to be due to Mab infection by molecular and clinical diagnosis and received species specific-antibiotics therapy. All were periodically monitored for the sputum smear and culture conversions throughout the treatment period. The clinical course was variable though all received similar antibiotic regimen and showed varied treatment outcomes. The time of diagnosis and the treatment outcome indicate that a better understanding of host-pathogen interactions is essential for the successful treatment of pulmonary Mab infection.
引用
收藏
页码:93 / 97
页数:5
相关论文
共 21 条
  • [1] In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium abscessus Complex
    Brown-Elliott, Barbara A.
    Wallace, Richard J., Jr.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (02)
  • [2] In vitro Activity of Seven Hospital Biocides against Mycobacterium abscessus: Implications for Patients with Cystic Fibrosis
    Caskey, Steven
    Moore, John E.
    Rendall, Jacqueline C.
    [J]. INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY, 2018, 7 (01) : 45 - 47
  • [3] Chandrashekaran Satish, 2017, J Clin Tuberc Other Mycobact Dis, V9, P10, DOI 10.1016/j.jctube.2017.08.002
  • [4] Daley CL, 2020, CLIN INFECT DIS, V71, pE1, DOI 10.1093/cid/ciaa241
  • [5] Mycobacterium abscessus, an Emerging and Worrisome Pathogen among Cystic Fibrosis Patients
    Degiacomi, Giulia
    Sammartino, Jose Camilla
    Chiarelli, Laurent Roberto
    Riabova, Olga
    Makarov, Vadim
    Pasca, Maria Rosalia
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (23)
  • [6] Pacemaker site infection caused by Rapidly Growing Nontuberculous Mycobacteria (RGM)
    Devana, Jhansi Vani
    Calambur, Narasimhan
    Reddy, B. Ravinder
    [J]. BIOMEDICAL AND BIOTECHNOLOGY RESEARCH JOURNAL, 2018, 2 (01): : 82 - 84
  • [7] Outcomes of pulmonary Mycobacterium abscessus infection
    Flight, William G.
    Hough, Natasha E.
    Chapman, Stephen J.
    [J]. INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY, 2020, 9 (01) : 48 - 52
  • [8] Gomathy N S, 2019, Indian J Tuberc, V66, P461, DOI 10.1016/j.ijtb.2019.04.013
  • [9] An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases
    Griffith, David E.
    Aksamit, Timothy
    Brown-Elliott, Barbara A.
    Catanzaro, Antonino
    Daley, Charles
    Gordin, Fred
    Holland, Steven M.
    Horsburgh, Robert
    Huitt, Gwen
    Iademarco, Michael F.
    Iseman, Michael
    Olivier, Kenneth
    Ruoss, Stephen
    von Reyn, C. Fordham
    Wallace, Richard J., Jr.
    Winthrop, Kevin
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 175 (04) : 367 - 416
  • [10] Griffith David E, 2016, F1000Res, V5, P2797